| Name: | Afatinib N-Oxide Impurity |
| Catalogue No. | VL5510023 |
| CAS No. | N/A |
| Molecular Formula | C24H25ClFN5O4 |
| Molecular Weight | 501.94 |
| Status | Under Development |
| IUPAC Name | (S,Z)-4-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-N,N-dimethyl-4-oxobut-2-en-1-amine oxide |
| Description | Afatinib N-Oxide Impurity(CAS No: N/A) or (S,Z)-4-((4-((3-chloro-4-fluorophenyl)amino)-7-((tetrahydrofuran-3-yl)oxy)quinazolin-6-yl)amino)-N,N-dimethyl-4-oxobut-2-en-1-amine oxide, is a potent and selective, irreversible tyrosine kinase inhibitor, |
| References | Ricciuti, Biagio, et al. “Afatinib in the First-Line Treatment of Patients with Non-Small Cell Lung Cancer: Clinical Evidence and Experience.” Therapeutic Advances in Respiratory Disease, vol. 12, 25 Oct. 2018, p. 1753466618808659, www.ncbi.nlm.nih.gov/pmc/articles/PMC6204616/, 10.1177/1753466618808659. |
